NRP1 and melanoma: Notably, parental melanoma cells sensitive to BRAF inhibitors were not affected by Gal-1-targeting siRNAs or a peptidomimetic inhibitor, which is consistent with the fact that the receptor NRP1 is almost undetectable and that the autocrine signaling circuit described here is not active in these cells.